Navigation Links
Gen-Probe Reports Strong Financial Results for Fourth Quarter and Full Year 2008
Date:2/17/2009

, an increase of 3% that resulted primarily from higher short-term investment balances. For the full year 2008, total other income was $15.5 million, compared to $12.3 million in the prior year period, an increase of 26% that also resulted from higher short-term investment balances.

Gen-Probe continues to have a strong balance sheet. As of December 31, 2008, the Company had $505.2 million of cash, cash equivalents and short-term investments, and no debt. In the fourth quarter of 2008, the Company repurchased approximately 1.5 million shares of its common stock for $65 million. For the full year 2008, Gen-Probe generated net cash of $178.3 million from its operating activities, compared to the Company's net income of $107.0 million.

2009 Financial Guidance

Gen-Probe provided its initial 2009 financial guidance via a press release issued on January 27, 2009.

"We expect 2009 to be another year of solid underlying earnings growth for Gen-Probe, although previously disclosed non-recurring items that added approximately $32 million of revenue and $0.34 of EPS will make comparisons to 2008 difficult," said Herm Rosenman, the Company's senior vice president of finance and chief financial officer.

Gen-Probe's 2009 guidance excludes revenue and expense associated with the pending Tepnel acquisition, which is expected to close in the second quarter, as well as any incremental revenue from the PROCLEIX ULTRIO assay in the United States. For the full year 2009, the Company expects the following on a GAAP basis:

                                        2009 Guidance
    Total revenues              $460 million to $490 million
    Product gross margins                   69-72%
    R&D expenses                            20-22%
    Marketing and sales expenses            10-11%
    G&A expenses                            10-11%
    Tax ra
'/>"/>
SOURCE Gen-Probe Incorporated
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14

Related medicine news :

1. Gen-Probe to Acquire Tepnel Life Sciences, Fast-Growing European Molecular Diagnostics Company, for 92.8 Million Pounds Sterling ($132.2 Million) in Cash
2. Gen-Probe and Novartis Agree to Extend and Expand Blood Screening Collaboration
3. Eric Tardif Joins Gen-Probe as Senior Vice President, Corporate Strategy
4. Gen-Probe to Webcast Presentation at the 27th Annual J.P. Morgan Healthcare Conference
5. Gen-Probe to Webcast Presentation at the 20th Annual Piper Jaffray Health Care Conference
6. Gen-Probe Reports Strong Financial Results for Third Quarter 2008, Raises Full-Year EPS Guidance
7. Gen-Probe Announces Webcasts of Three Upcoming Investor Events
8. Gen-Probe to Webcast Two Upcoming Investor Presentations
9. Gen-Probe Announces Webcast of First Quarter 2008 Earnings Conference Call
10. Gen-Probe to Webcast Presentation at Leerink Swann Molecular Diagnostics Conference
11. Gen-Probe to Webcast Presentation at Deutsche Bank Small- and Mid-Cap Growth Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/2/2014)... York, NY (PRWEB) September 02, 2014 ... VisitandCare.com , was designed to help doctors manage ... practices to boost patient conversion rates and clink revenue. ... a 60 percent increase in sales revenue and a ... one-of-a-kind CRM software in their own healthcare practices. , ...
(Date:9/2/2014)... California, San Diego School of Medicine have identified an ... The findings, reported in the current issue of PNAS, ... mortality worldwide. An estimated 40,000 women in America will ... American Cancer Society. , "The take-home message of the ... target breast cancer metastasis through a pathway regulated by ...
(Date:9/2/2014)... (PRWEB) September 02, 2014 For the ... IT security and network services company, has been named ... Inc. magazine's Inc. 5000 list highlights America's fastest growing ... year since the list inception in 2007. , Landing ... grown 144 percent over the past three years. , ...
(Date:9/2/2014)... (trade name: Betmiga) has been approved since December 2012 ... an early benefit assessment pursuant to the Act on ... the German Institute for Quality and Efficiency in Health ... added benefit over the appropriate comparator therapy specified by ... advantage with regard to side effects: Dry mouth was ...
(Date:9/2/2014)... A New York City based company is ... yet revolutionary, product that will have far-reaching, ... care costs for Americans. , REMIND-A-CAP™ is ... control in the user's hands. It's a simple device ... date of intake by simply turning a knob. No ...
Breaking Medicine News(10 mins):Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 2Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 3Health News:Doctors Abroad Using VisitandCare.com Patient Management Software Report 60% Increase in Revenue 4Health News:Enzyme controlling metastasis of breast cancer identified 2Health News:CentraComm Named to Inc. 5000 for 8th Consecutive Year 2Health News:Mirabegron for overactive bladder: Added benefit not proven 2Health News:Mirabegron for overactive bladder: Added benefit not proven 3Health News:REMIND-A-CAP™ , A New York City Based Company Invents Groundbreaking Prescription Cap to Curb Non-Adherence 2
... first discovered in China nearly 5000 years ago, has ... heart disease, stroke and certain types of cancer. Researchers ... two compounds found in green tea, EGCG (epigallocatchin gallate) ... blocking the enzyme that destroys cartilage. Dr David Buttle, ...
... Venous thromboembolism is a condition which causes clotting in ... five- to 10-day course of heparin followed by three ... the problem with this treatment is that once the ... rates of this problem are reduced if the patient ...
... in the February issue of the British Medical Journal has ... at risk of heart disease later in life than those ... infant in Scotland during the years 1981-85, were identified as ... or repeated miscarriages. Then, during 1981 to 1999, the researchers ...
... a common problem in the knees, is a form ... change. A key problem involved in in these type ... salt called hyaluronan within the fluid that moisturizes the ... injections are being given to humans since 1987, after ...
... in appetite control, called ghrelin, has been identified by ... have demonstrated the effect of the hormone on the ... specialized neurons in the hypothalamus involved in weight regulation. ... the ability to stimulate feeding when introduced to specialized ...
... not all that well understood, but is believed to ... winter months. Winter depression involves suffering from feelings of ... and nights get shorter. Other SAD symptoms include overeating, ... than usual. Researchers have now found that light therapy// ...
Cached Medicine News:Health News:Treatment over a longer period for blood clotting 2Health News:Miscarriage during pregnancy and heart disease linked 2Health News:Scientists locate key hormone involved in appetite control 2
(Date:9/2/2014)... 2014  Ameritox SM , the nation,s leader in ... Drugs to Heroin," a research report that provides concrete ... examines deadly trends that have created a unique heroin ... The report is based on data ... It examines five trends that distinguish the heroin abuse ...
(Date:9/2/2014)... , Spanje, September 2, 2014 ... GARFIELD AF Registry bij het ESC CONGRESS ... bij patiënten met risico op beroerte in ... Gegevens van bijna 12.500 patiënten ingeschreven ... FIELD-Atrial Fibrillation (GARFIELD-AF), een innovatief, onafhankelijk initiatief ...
(Date:9/2/2014)... 2014 Donald Spector , a renowned ... 8,823,512 for a Wearable Biosensor, which will issue today, ... this field.  Mr. Spector holds some of the earliest ... made today by New York College of Health Professions, ... of world-class intellectual properties.  New York College noted that ...
Breaking Medicine Technology:Ameritox Research Report Reveals Pain Patients' Role in Current Heroin Epidemic 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 2Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 3Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 4Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 5Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 6Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 7Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 8Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 9Gegevens uit wereldwijde atriumfibrillatieregister tonen aan dat antistollingsmiddelen niet optimaal worden gebruikt ter preventie van beroerte 10Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 2Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 3Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 4Wearable Biosensor Patent, the Grandfather of Wearable Biosensor Transmission Patents, Granted to Donald Spector, One of the Most Prolific Living Inventors in the World 5
... AMN Healthcare Services, Inc. (NYSE: AHS ), the largest ... quarterly conference call to discuss third quarter results on Thursday, ... also expects to issue an earnings news release on Thursday, ... 4:00 p.m. Eastern Time. , A live webcast of the ...
... CPhI Worldwide and connected events - the global pharma ingredients and ... - 15 October for its 20th staging. , The co-located ... technology events are joined for 2009 under the Where Pharma ... The new platform markedly reflects the notable convergence of the pharma ...
Cached Medicine Technology:AMN Healthcare Services to Host 2009 Third Quarter Earnings Conference Call on Thursday, October 29, 2009 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 2CPhI 2009: Madrid Launch for BioPh Marks Pharma and Biotech Convergence 3
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Cushing-Hopkins periosteal elevator, Gutsch handle, blade width 7/16" (11 mm), length 7 5/8" (194 mm)....
Cushing Little Joker periosteal elevators, solid handle, blade width 1/4" (6 mm), length 7 1/2" (191 mm)....
Lederer periosteal elevators....
Medicine Products: